Monitor AST/ALT, HBV envelope antigen, HBV surface antigen, and HBV DNA levels every 3 months for first year of therapy and annually thereafter during treatment.
HIV antibody testing should be offered to all patients.
Monitor hepatic function for several months after discontinuing therapy.
Monitor renal function at baseline and during therapy, especially in the elderly and in liver transplant patients on immunosuppressants.
Monitor urinalysis and serum phosphate prior to therapy and at least annually during therapy.